Lenvatinib en Cáncer Diferenciado de Tiroides: Respuestas tras la Refractariedad al Radioyodo - page 5

Sorafenib vs Lenvatinib in Thyroid Cancer

RET/PTC

Brose MS, et al.

BMC

, 2011

Stjepanovic N and Capdevila J

Biologics

, 2014

Sorafenib

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4 6,7,8,9,10,11,12,13,14,15,...27